| Document Date: 2009-03-31 14:51:02
Open Document File Size: 394,73 KBShare Result on Facebook
Company ACE / / IndustryTerm treatment of congestive heart failure / aqueous solutions / treatment algorithm / food / / MedicalCondition pulmonary hypertension secondary / pulmonary artery pressure / abdominal pain / potential liver injury / severe chronic heart failure / Congestive Heart Failure / Potential liver injury TRACLEER / marked oligospermia / hypertension / HIV / disease / scleroderma / liver dysfunction / left ventricular dysfunction / dyspnea / primary pulmonary hypertension / liver failure / pulmonary arterial hypertension / connective tissue diseases / nausea / recurrent pulmonary emboli / pulmonary vascular resistance / pulmonary hypertension / fever / unexplained hepatic cirrhosis / vomiting / unusual lethargy / fatigue / pulmonary / injury / heart failure / pulmonary edema / Hypersensitivity / PVOD / liver injury / potential serious liver injury / increased liver injury / serious liver injury / baseline disease / HIV disease / autoimmune diseases / / MedicalTreatment contraception / contraceptive method / drug therapies / / Organization Potential Liver Injury and DOSAGE AND ADMINISTRATION / World Health Organization / ETA / DOSAGE AND ADMINISTRATION / ETB / / / Position physician / Fisher / gynecologist / Pharmacokinetics General / / Product talc / Cyclosporine / digoxin / Glyburide / TRACLEER / / PublishedMedium the TRACLEER® Medication Guide / / Technology Pharmacokinetics / treatment algorithm / /
SocialTag |
TRACLEER® [bosentan[removed]mg and 125 mg film-coated tablets Use of TRACLEER® requires attention to two significant concerns: 1) potential for serious liver injury, and 2) potential damage to a fetus.